JNJ vs SBUX: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-20.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
Starbucks Corporation · Consumer Cyclical
$96.60
-12.3% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
SBUX |
| Current Price |
$230.69 |
$96.60 |
| Fair Value Estimate |
$255.61 |
$84.75 |
| Upside to Fair Value |
+10.8%
|
-12.3%
|
| Market Cap |
$555.9B |
$110.1B |
| Forward P/E |
26.8x
|
42.2x
|
| EV / EBITDA |
18.5x
|
22.5x
|
| Price / Sales |
5.8x
|
3.0x
|
| Price / FCF |
28.2x
|
45.1x
|
| Revenue Growth YoY |
+9.9%
|
+2.8%
|
| Gross Margin |
69.1%
|
24.2%
|
| Operating Margin |
26.9%
|
9.6%
|
| Return on Equity |
26.5%
|
-22.9%
|
| Dividend Yield |
0% |
2.55% |
| FCF Yield |
3.54%
|
2.2%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Starbucks is the world's largest specialty coffee retailer with over 39,000 stores across 86 markets, generating $37.2B in annual revenue. Under CEO Brian Niccol, now 19 months into his tenure after joining from Chipotle in September 2024, the company is executing the Back to Starbucks operational turnaround focused on service speed, menu simplification, and store experience reinvention. At P/S 2…
Accumulation Zones
| Metric |
JNJ |
SBUX |
| Zone Low |
$191.71 |
$63.56 |
| Zone High |
$217.27 |
$72.04 |
| In Buy Zone? |
No
|
No
|